AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1386490
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 to 80 mg daily in slow-release form)
Trial: 24632753
Drug: Lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir 400/100 mg twice a day plus nucleoside reverse transcriptase inhibitors
Trial: 15490983
Drug: Imipenem/cilastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin monotherapy
Trial: 1552197
Drug: Aminoglycoside therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglycoside therapy
Trial: 2571295
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme inhibitors
Trial: 22717418
Drug: IRO‐A 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRO‐A 1 × 5 mg
Trial: 22717418
Drug: IRO‐A and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRO‐A and IRO tablets (safety profile)
Trial: 20379676
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) - no surface treatment
Trial: 18053120
Drug: 0.0125 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0125 mg/kg/d of GH subcutaneously added to standard therapy
Trial: 8476802
Drug: 15 min
RxNorm normalized name: Carmex Daily Care Moisturizing Lip Balm SPF 15 Minis KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 min incremental oxytocin infusion
Trial: 3774206
Drug: Pirenzepine (PRZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PRZ) 50 mg/day
Trial: 3774206
Drug: Pirenzepine (PRZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PRZ) 100 mg/day
Trial: 30232854
Drug: Medication (Metformin)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Metformin)
Trial: 30304712
Drug: Greater injection
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater injection self-efficacy
Trial: 27277211
Drug: Low protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protamine dosing (0.8 protamine-to-heparin ratio; n=49)
Trial: 27277211
Drug: High protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protamine dosing (1.3 protamine-to-heparin ratio; n=47)
Trial: 14696681
Drug: Acupressure at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure at Neiguan (PC-6), Zusanli (ST-36), and Sanyinjiao (SP-6) for 3 minutes, twice a day
Trial: 8468440
Drug: moclobemide, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide, 450 mg/day
Trial: 3545141
Drug: Ketoconazole, 200
RxNorm normalized name: Ketoconazole, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole, 200 mg via the gastrointestinal tract daily for 21 days or until one week after discharge from the SICU.
Trial: 16893381
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg
Trial: 12145058
Drug: Tizanidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (4 mg)
Trial: 8139083
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks
Trial: 8139083
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks
Trial: 8707476
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment
Trial: 11897546
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg
Trial: 12947359
Drug: Warfarin (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted to INR 2.0-3.0)
Trial: 12947359
Drug: Ximelagatran (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (36 mg bid)
Trial: 1867581
Drug: Nimorazole 1
RxNorm normalized name: nimorazole 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole 1 g per day for 7 days (Group III)
Trial: 6817770
Drug: Bupropion 100
RxNorm normalized name: buPROPion 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 100 mg + Diazepam 5 mg
Trial: 25876339
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg tablet once every night for 4 weeks, increased to 10 mg tablet after 4 weeks)
Trial: 22985998
Drug: Family-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused cognitive behaviour therapy (CBT)
Trial: 29537447
Drug: Oxymetazoline cream
RxNorm normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline cream 1.0%
Trial: 21879233
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation (PMR) therapy
Trial: 14557446
Drug: Flutamide-metformin added
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide-metformin added to gestodene-containing OC in OC+ women
Trial: 11783156
Drug: Yixin oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yixin oral liquid (YXOL)
Trial: 11783156
Drug: Shuxinsu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxinsu capsule (SXSC) and openly treated group (OTG)
Trial: 2196623
Drug: Fluoxetine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (various doses)
Trial: 28808791
Drug: Control (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (25 mL soybean oil daily)
Trial: 12687805
Drug: Lateral sites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral sites (AL + L + PL CST, 134 patients)
Trial: 6248395
Drug: Fenoterol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (5 mg)
Trial: 24421266
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of APP before injection of polyI:C
Trial: 22797003
Drug: β‐alanine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐alanine supplementation (BA, 2 × 800 mg tablets, 3 times daily)
Trial: 22797003
Drug: Placebo (PL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL, 2 × 800 mg maltodextrin tablets, 3 times daily)
Trial: 17359403
Drug: 1 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg(‐1) midazolam (group H)
Trial: 17359403
Drug: 0.5 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg(‐1) midazolam (group L)
Trial: 7613796
Drug: Indoramin (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (alpha 1-adrenergic blocker)
Trial: 150142
Drug: Control preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control preparation (Betamethasone valerate + Gentamicin + Tolnaftate + Clioquinol)
Trial: 25274197
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) and exercise
Trial: 25274197
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (placebo HILT) and exercise
Trial: 21109517
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment regimens for ANCA-associated vasculitis
Trial: 17699491
Drug: Placebo (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3.6 g of granulate each day)
Trial: 3986086
Drug: Alpha-methyldopa (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-methyldopa (750 mg)
Trial: 29763353
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri probiotic lozenges (n = 90)
Trial: 29763353
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (n = 88)
Trial: 28744807
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (5 mg/kg bolus loading dose and 1 mg/kg continuous infusion)
Trial: 28744807
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (10 mg/kg bolus loading dose and 2 mg/kg continuous infusion)
Trial: 23124782
Drug: PA21 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 10 g/d
Trial: 23124782
Drug: PA21 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 12.5 g/d
Trial: 23124782
Drug: PA21 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 5.0 g/d
Trial: 23124782
Drug: PA21 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA21 7.5 g/d
Trial: 23124782
Drug: Sevelamer-HCl 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer-HCl 4.8 g/d
Trial: 10731543
Drug: Half-dose nafarelin
RxNorm normalized name: nafarelin Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose nafarelin treatment (200 microgram daily) for 20 weeks after 4 weeks of full-dose nafarelin (n = 8)
Trial: 8736459
Drug: Betaxolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol monotherapy (5-10 mg daily for 6 months)
Trial: 8736459
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with betaxolol and nitrendipine (10-20 mg once daily from month 7 to 12)
Trial: 20722793
Drug: Medicinal plants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal plants (e.g., Ferula hermonis, Angelica sinensis, Ginkgo biloba)
Trial: 7956409
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefonicid daily intravenously started at chest tube insertion and stopped within 24 h of removal
Trial: 7956409
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefonicid daily intravenously
Trial: 2892450
Drug: Cetirizine 20
RxNorm normalized name: cetirizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 20 mg
Trial: 2892450
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg
Trial: 29877995
Drug: Web-based calculator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based calculator tool for communicating estimates of personalized treatment outcomes
Trial: 18673417
Drug: Physiotherapy (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy (five times daily using inter-positioning tongue spatulas, adding a new spatula every 5-10 days)
Trial: 18673417
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of hyaluronidase with steroids
Trial: 25938628
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment
Trial: 11340797
Drug: Specific speech
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific speech and language therapy (SLT) including a portable metronome brooch to cue swallowing
Trial: 11340797
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of botulinum toxin into both parotid glands
Trial: 10660242
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 3 microg/kg
Trial: 7715908
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous IL-2 (3 million IU/day for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally)
Trial: 339662
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg daily during three consecutive days, every fortnight)
Trial: 31496316
Drug: Periulcer foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periulcer foam sclerotherapy injection using Aethoxysklerol 1%
Trial: 31496316
Drug: Periulcer foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periulcer foam sclerotherapy injection
Trial: 25994074
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion (2 pmol kg(‐1) min(‐1))
Trial: 25994074
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Trial: 25994074
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Trial: 25994074
Drug: Sole GIP
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole GIP infusion
Trial: 3197373
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (154 mmol/l NaCl)
Trial: 25994074
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Trial: 25994074
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Trial: 25994074
Drug: Sole placebo
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole placebo infusion
Trial: 18979143
Drug: Nizatidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg bd)
Trial: 9294990
Drug: Pravastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin + Gemfibrozil (20 mg + 1200 mg/day)
Trial: 9294990
Drug: Simvastatin +
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin + Gemfibrozil (20 mg + 1200 mg/day)
Trial: 9294990
Drug: Simvastatin +
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin + Ciprofibrate (20 mg + 100 mg/day)
Trial: 9294990
Drug: All combination
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All combination treatments
Trial: 20399985
Drug: Ziprasidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (20 and 30 mg)
Trial: 20399985
Drug: Haloperidol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (7.5 and 10 mg)
Trial: 12882611
Drug: Phonophoresis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis of ketoprofen gel using continuous ultrasound (1 MHz, 1.5 W/cm2, for 5 minutes)
Trial: 12882611
Drug: Phonophoresis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis of ketoprofen gel using pulsed ultrasound (100 Hz, 20% duty cycle)
Trial: 8895048
Drug: Alpha-glucosidase inhibitor
RxNorm normalized name: Alpha-glucosidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-glucosidase inhibitor replacing part of insulin in Group 2 (n = 10)
Trial: 1900686
Drug: Induced Hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced Hypertension Chemotherapy (IHC) using angiotensin II human (TY-10721) with adriamycin (33 mg/m2, day 3), 5-fluorouracil (330 mg/m2/day through day 1 to 3, 8 to 10), and mitomycin C (5 mg/m2, day 8), repeated every 4 weeks.
Trial: 26768436
Drug: gabapentin +
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gabapentin + dexamethasone + 5HT3 receptor antagonist
Trial: 1535579
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg
Trial: 16200718
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 1 (G1)
Trial: 16200718
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 2 (G2)
Trial: 9029746
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered immediately after pholcodine (25 g)
Trial: 9029746
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal administered 2 hours after pholcodine (25 g)
Trial: 9029746
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of activated charcoal (10 g every 12 h for 84 h)
Trial: 9029746
Drug: Pholcodine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pholcodine administered on an empty stomach with water only (100 mg)
Trial: 3310941
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of administered norfloxacin twice daily for three days
Trial: 3310941
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days
Trial: 18467316
Drug: Induction chemoradiotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemoradiotherapy (CHRT) with 60 Gy, infusional 5-FU (300 mg/m²/day for 6 weeks), and intermittent cisplatin (20 mg/m²/day during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Trial: 12865191
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (oestradiol valerate and medroxyprogesterone acetate)
Trial: 8880021
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg acetylsalicylic acid
Trial: 25025755
Drug: Nilotinib 300
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300 mg BID
Trial: 25025755
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg BID
Trial: 21682350
Drug: DRV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r monotherapy (800/100 mg once daily)
Trial: 20010070
Drug: DRV/r with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r with two nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 17346436
Drug: PMBL sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMBL sublingual treatment
Trial: 14582440
Drug: Trimetazidine and
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine and perindopril (combined treatment)
Trial: 30053212
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 1000 mg × 2 doses at 0, 15 days
Trial: 30053212
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) 500 mg/m2 monthly
Trial: 12839279
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zinc daily for 5 days a week for 16 weeks
Trial: 6476319
Drug: Atropine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.6 mg intravenously
Trial: 9884857
Drug: Glycopyrrolate 0.2
RxNorm normalized name: glycopyrrolate 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.2 mg intravenously
Trial: 21109132
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (1.5 mg/kg propofol)
Trial: 21109132
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (2 mg/kg propofol)
Trial: 8594696
Drug: DEC 6
RxNorm normalized name: Zodryl DEC 60 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 6 mg/kg alone
Trial: 8594696
Drug: IVR 400
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVR 400 micrograms/kg plus DEC 3 mg/kg
Trial: 2706316
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sustained-release methylphenidate (SR)
Trial: 2706316
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg immediate-release methylphenidate (IR)
Trial: 2706316
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of SR formulations